Oncology Articles

FDA Approves Lenvatinib for Frontline HCC
The FDA has approved lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma.
SL-401 Emerging as First Targeted Therapy for Rare Blood Cancer
Naveen Pemmaraju, MD, discusses SL-401 and the future of treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Updates Continue in Oncogene-Driven Lung Cancer
Jose M. Pacheco, MD, discusses the preferred therapeutic strategies for treating patients with NSCLC whose tumors harbor genetic alterations in EGFR, ALK, and ROS1.
Novel Combination Shows Early Efficacy in Ovarian Cancer
David O'Malley, MD, discusses the emerging combination of mirvetuximab soravtansine plus bevacizumab and the evolving treatment landscape in ovarian cancer.
Drilon Discusses Promise of LOXO-292 in RET-Altered Solid Tumors
Alexander E. Drilon, MD, discusses the data with LOXO-292 thus far and the promise for this agent in patients with RET alterations.
CDK4/6 Inhibitors, Other Treatment Advances Show Hope for Patients With Breast Cancer
Stephanie L. Graff, MD, discusses the current and evolving landscape of breast oncology and what this means for patients.
Expert Explains Work Needed for Immunotherapy/RT Approaches in NSCLC
James Larner, MD, discusses the process by which radiation interacts with the immune system and how physicians are working to improve treatment responses for patients with non–small cell lung cancer.
Barr Bridges Past and Present Treatment of Neuroendocrine Tumors
Jodie Barr, DO, discusses the evolution of treatment of patients with neuroendocrine tumors and the need for biomarkers.
Immunotherapy Data Lead Lung Cancer Landscape Following ASCO 2018
Apar Kishor Ganti, MD, discusses some of the most intriguing abstracts in lung cancer recently presented at medical meetings.
Importance of NGS and Targetable Mutations Stressed in AML
Suman Kambhampati, MD, discusses the impact of next-generation sequencing on treatment selection, updates in the inhibition of BCL-2, IDH1/2, and FLT3-ITD, and new agents on the horizon for the treatment of patients with acute myeloid leukemia.
Publication Bottom Border
Border Publication